Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

The decision to divest Opella is part of Sanofi’s ongoing strategy to become ... The medicine is so popular that most paracetamol products are referred to as Doliprane, regardless of the ...

Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in ...

SNY’s recent Opella divestiture marks a pivot ... it shows this company continues working on new products that have blockbuster potential. Sanofi's R&D Collaborations and Strategy I also like ...

The company is projected to receive substantial proceeds from the Opella transaction ... Sanofi engages in the research, production and distribution of pharmaceutical products.

CFO Roger clarified it was designed to mitigate Opella dilution ... impacting market share. Sanofi delivered robust Q4 2024 results with strong growth across key products and new launches ...

Sanofi intends to sell a controlling stake in Opella to a private equity firm ... Higher sales of Dupixent and contributions from new products like Altuviiio, and Beyfortus were partially offset ...